Novo Nordisk A/S
לונג

NVO – Long-Term Cycle View (5–7 Years)

370
Thesis
NVO is transitioning from a completed Cycle Wave 2 into a new multi-year expansion phase. The long-term bull structure remains intact, with fundamentals now acting as a catalyst for the next cycle leg.

Context
- Weekly timeframe
- Primary bull trend originates from the 2009 GFC low (< $1)
- Cycle Wave 1 completed in July 2024
- Deep corrective Cycle Wave 2 now appears complete

What I see
-Structural reversal underway from long-term trend support
- Price stabilizing in a major accumulation / buy zone
- New Wegovy pill acts as a fundamental trigger aligning with the technical reversal
- Momentum and structure support the start of Cycle Wave 3

What matters now
- Holding the current base keeps the Cycle Wave 3 thesis intact
- This phase is about accumulation, not timing short-term moves

Buy / Accumulation zone
- Current zone remains suitable for long-term positioning
- This is where multi-year risk/reward is defined

Targets
- Cycle Wave 3 (1.618 Fib): ~$273. Expected around early 2029. Approx. +450% from the buy area
- Cycle Wave 5: ~$415. Expected around 2033. Approx. +730% from the buy area

Income
- Dividend yield ~2.1% adds meaningful carry while holding

Conclusion
Strong technical cycle alignment + improving fundamentals make NVO a compelling long-term hold. This is a position built to be held through volatility, not traded.

כתב ויתור

המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.